EUVIMEDOpdag EUVIMED
Crossref

Design and Synthesis of New Triazol Derivatives as Aromatase Enzyme Inhibitors

Abdullah Çelik, Hayrani Eren Bostancı, Şennur Görgülü iD, Mehmet Taha Yıldız, Ulviye Acar Çevik iD

Chemical Biology & Drug Design · 2026-03 · 107 (3)

DOI: 10.1111/cbdd.70276 ↗

At a glance

Journal article in Chemical Biology & Drug Design, published online on 2026-03-12. Written by Abdullah Çelik and 4 co-authors. Institution: Department of Pharmacy, Eskişehir Osmangazi Unıversity Health, Practice and Research Hospital, Eskisehir, Turkey. Major MEDLINE topics: Triazoles, Aromatase Inhibitors, Aromatase, Drug Design. Cited 1 times so far (Crossref); 24 references.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

In this study, novel triazole derivatives were designed and synthesized for potential breast cancer treatment. A series of 1,2,4‐triazole compounds bearing a 2,4‐difluorophenyl moiety ( 3a–3r ) was obtained through a two‐step organic synthesis process. The anticancer activities of the synthesized compounds were evaluated using the MTT assay in MCF‐7 and L929 cell lines, and some derivatives ( 3d, 3h, 3k, 3n ) exhibited selective cytotoxicity. The inhibitory effects of these compounds on the aromatase enzyme were determined and compared with those of letrozole. Molecular docking studies were performed to investigate the interactions of the most active compounds with the aromatase enzyme's active site, revealing binding energies and amino acid interactions. Finally, the ADME profiles of the lead compounds were assessed to analyze their pharmacokinetic properties. The findings suggest that the selected triazole derivatives may be promising novel candidates for aromatase inhibition in breast cancer therapy.

Subjects

MeSH terms (MEDLINE)

TriazolesAromatase InhibitorsAromataseDrug DesignAntineoplastic AgentsHumansMolecular Docking SimulationMCF-7 CellsCatalytic DomainCell Line, TumorFemaleLetrozoleAnimalsStructure-Activity RelationshipBreast Neoplasms

Author keywords

1,2,4‐triazolearomatasebreast cancercytotoxicitymolecular docking

Substances

TriazolesAromatase InhibitorsAromataseAntineoplastic AgentsLetrozole

Authors and institutions

  • Department of Pharmacy, Eskişehir Osmangazi Unıversity Health, Practice and Research Hospital, Eskisehir, Turkey.
  • Institute of Graduate Education, Anadolu University, Eskisehir, Turkey.
  • Department of Biochemistry Sivas, Sivas Cumhuriyet University, Faculty of Pharmacy, Sivas, Turkiye.
  • Medicinal Plant, Drug and Scientific Research and Application Center (AUBIBAM), Eskişehir, Turkey.
  • Hamidiye Faculty of Health Sciences, University of Health Sciences, Istanbul, Turkey.
  • Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Anadolu University, Eskişehir, Turkey.

ORCID profiles: Şennur Görgülü, Ulviye Acar Çevik

Cite

APA

Çelik, A., Bostancı, H. E., Görgülü, Ş., Yıldız, M. T., & Acar Çevik, U. (2026). Design and Synthesis of New Triazol Derivatives as Aromatase Enzyme Inhibitors. Chemical Biology & Drug Design, 107(3). https://doi.org/10.1111/cbdd.70276

Vancouver

Çelik A, Bostancı HE, Görgülü Ş, Yıldız MT, Acar Çevik U. Design and Synthesis of New Triazol Derivatives as Aromatase Enzyme Inhibitors. Chemical Biology & Drug Design. 2026;107(3). doi:10.1111/cbdd.70276

BibTeX
@article{elik2026,
  author = {Çelik, Abdullah and Bostancı, Hayrani Eren and Görgülü, Şennur and Yıldız, Mehmet Taha and Acar Çevik, Ulviye},
  title = {Design and Synthesis of New Triazol Derivatives as Aromatase Enzyme Inhibitors},
  journal = {Chemical Biology & Drug Design},
  year = {2026},
  volume = {107},
  number = {3},
  doi = {10.1111/cbdd.70276}
}
Start for free →